ClinicalTrials.gg
CompletedNCT00154102CRYSTALUpdated Jan 30, 2017Results posted

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

A Phase 3 interventional study of Cetuximab and FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) in Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 154 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-30.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
6th of 185
1,221 · median 60
Started
2004
with 9 others
Phase 3
29 of 187
5 open now
Registered
15th of 187
by date
Lead sponsor
4 of 187
Merck KGaA, Darmstadt, Germany

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 6th largest by enrollment of the 185 interventional ones that give a count, is one of 10 that started in 2004, is one of 29 in phase 3, and was the 15th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving combination chemotherapy together with cetuximab as first treatment after diagnosis of a metastatic colorectal cancer ('1st-line' treatment) may improve the treatment efficacy. However, it is not yet known whether giving combination chemotherapy together with cetuximab is more effective than combination chemotherapy alone. This open-label trial investigates the effectiveness of cetuximab in combination with a standard and effective chemotherapy (5-Fluorouracil (5FU)/Folinic acid (FA) plus irinotecan) for metastatic colorectal cancer in first-line setting, compared to the same chemotherapy alone on patient expressing the epidermal growth factor (EGF) receptor.

Patients expressing this EGF Receptor will be randomly assign in one of the 2 groups to either receive the combination chemotherapy alone or with cetuximab (open-label study) and will then be treated until progression of the disease or unacceptable toxicity occur. Regular efficacy assessments (every 8 weeks) based on imaging will be performed throughout the study together with regular safety assessments (e.g. safety labs). An independent Safety Board of experts will also monitor safety data.

After participant discontinuation from the trial, regular updates on further treatments and survival status will be requested from the investigator.

The entire study (from the first patient entering the study to the last collect of follow-up information) is 4-5 years long.

03

Conditions studied

  • Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Keywords

  • Metastatic colorectal cancer
  • EGFR
  • Irinotecan
  • cetuximab
  • first-line treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of confirmed adenocarcinoma of the colon or rectum
  • Inoperable disease
  • Immunohistochemical evidence of epidermal growth factor receptor expression in tumor tissue
  • Presence of at least 1 bi-dimensionally measurable index lesion

Exclusion criteria

Exclusion Criteria:

  • Previous irinotecan-based chemotherapy
  • Previous chemotherapy for colorectal cancer except treatment if terminated more than 6 months before the start of study treatment
  • Radiotherapy, surgery (excluding prior diagnostic ) or any drug in the 30 days before the start of study treatment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,221 participants (actual)

Study arms

  • Experimental
    Cetuximab Plus FOLFIRI

    Drug: Cetuximab · Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

  • Active comparator
    FOLFIRI Alone

    Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Interventions

  • Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops

  • DrugFOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

    Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

    Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

    Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  2. Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments

    Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

    Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  3. Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

    Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

    Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Secondary outcomes

  1. Overall Survival Time (OS)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.

    Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

  2. Overall Survival Time (KRAS Wild-Type Population)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.

    Time frame: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

  3. Overall Survival Time (KRAS Mutant Population)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.

    Time frame: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

  4. Best Overall Response Rate - Independent Review Committee (IRC) Assessments

    The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

    Time frame: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  5. Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments

    The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

    Time frame: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  6. Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

    The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

    Time frame: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  7. Disease Control Rate - Independent Review Committee (IRC) Assessments

    The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).

    Time frame: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  8. Duration of Response - Independent Review Committee (IRC) Assessments

    Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

    Time frame: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  9. Participants With No Residual Tumor After Metastatic Surgery

    Participants with no residual tumor after on-study surgery for metastases

    Time frame: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

  10. Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

    Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

    Time frame: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  11. Quality of Life Assessment (EORTC QLQ-C30) Social Functioning

    Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.

    Time frame: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

  12. Safety - Number of Patients Experiencing Any Adverse Event

    Please refer to Adverse Events section for further details

    Time frame: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

07

Results

Posted Feb 23, 2011
Limitations and caveats
A non-specific outcome measure 'Safety' was deleted from the entry in error. A replacement outcome was created. The outcome refers to adverse events.

Participant flow

First/Last subject in: 10 Aug 2004/4 Nov 2005. Clinical cut-off efficacy analyses except survival: 27 Jul 2006, Cut off date IRC data: 14 Dec 2006; cut-off safety analyses: 30 Nov 2007; cut-off survival analyses: 31 May 2009; cut-off KRAS analyses: 28 Aug 2009. 1221 subjects were randomised or treated, of whom 1198 were randomised and treated.

Participant flow — Overall Study
MilestoneCetuximab Plus FOLFIRIFOLFIRI Alone
Started599599
Completed592597
Not completed72
Withdrew: Investigational study phase ongoing72

Outcome measures

PrimaryProgression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

Time frame:
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Median · months
Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments8.9 (8.0 to 9.4)8.0 (7.6 to 9.0)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified log rank · p = 0.0479 · Hazard ratio (hr): 0.853 · 95% CI 0.728 to 1.000Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
PrimaryProgression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments

Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

Time frame:
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Median · months
Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments9.9 (9.0 to 11.3)8.4 (7.4 to 9.2)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified log rank · p = 0.0012 · Hazard ratio (hr): 0.696 · 95% CI 0.558 to 0.867Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
PrimaryProgression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

Time frame:
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Median · months
Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments7.4 (6.1 to 8.0)7.7 (7.3 to 9.2)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified log rank · p = 0.2648 · Hazard ratio (hr): 1.171 · 95% CI 0.887 to 1.544Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryOverall Survival Time (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.

Time frame:
Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Reported as:
Median · months
Overall Survival Time (OS)
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Overall Survival Time (OS)19.9 (18.5 to 21.3)18.6 (16.7 to 19.8)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified log rank · p = 0.0419 · Hazard ratio (hr): 0.878 · 95% CI 0.774 to 0.995Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryOverall Survival Time (KRAS Wild-Type Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.

Time frame:
Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Reported as:
Median · months
Overall Survival Time (KRAS Wild-Type Population)
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Overall Survival Time (KRAS Wild-Type Population)23.5 (21.2 to 26.3)20.0 (17.4 to 21.7)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified log rank · p = 0.0093 · Hazard ratio (hr): 0.796 · 95% CI 0.670 to 0.946Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryOverall Survival Time (KRAS Mutant Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.

Time frame:
Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Reported as:
Median · months
Overall Survival Time (KRAS Mutant Population)
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Overall Survival Time (KRAS Mutant Population)16.2 (14.9 to 17.9)16.7 (14.9 to 19.4)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified log rank · p = 0.7549 · Hazard ratio (hr): 1.035 · 95% CI 0.834 to 1.284Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryBest Overall Response Rate - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

Time frame:
evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Number · percentage of participants
Best Overall Response Rate - Independent Review Committee (IRC) Assessments
percentage of participantsCetuximab Plus FOLFIRIFOLFIRI Alone
Best Overall Response Rate - Independent Review Committee (IRC) Assessments46.9 (42.9 to 51.0)38.7 (34.8 to 42.8)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified cochran-mantel haenszel test · p = 0.0038 · Odds ratio (or): 1.40 · 95% CI 1.12 to 1.77
SecondaryBest Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

Time frame:
evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Number · percentage participants
Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments
percentage participantsCetuximab Plus FOLFIRIFOLFIRI Alone
Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments57.3 (51.6 to 62.8)39.7 (34.6 to 45.1)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.069 · 95% CI 1.515 to 2.826
SecondaryBest Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).

Time frame:
evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Number · percentage of participants
Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
percentage of participantsCetuximab Plus FOLFIRIFOLFIRI Alone
Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments31.3 (25.2 to 38.0)36.1 (29.1 to 43.5)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Cochran-Mantel-Haenszel · p = 0.3475 · Odds ratio (or): 0.822 · 95% CI 0.544 to 1.242
SecondaryDisease Control Rate - Independent Review Committee (IRC) Assessments

The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).

Time frame:
Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Number · percentage of participants
Disease Control Rate - Independent Review Committee (IRC) Assessments
percentage of participantsCetuximab Plus FOLFIRIFOLFIRI Alone
Disease Control Rate - Independent Review Committee (IRC) Assessments84.3 (81.1 to 87.1)85.5 (82.4 to 88.2)
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Stratified cochran-mantel haenszel test · p = 0.6004 · Odds ratio (or): 0.92 · 95% CI 0.67 to 1.26
SecondaryDuration of Response - Independent Review Committee (IRC) Assessments

Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

Time frame:
Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Median · months
Duration of Response - Independent Review Committee (IRC) Assessments
monthsCetuximab Plus FOLFIRIFOLFIRI Alone
Duration of Response - Independent Review Committee (IRC) Assessments9.6 (9.1 to 12.9)7.7 (6.7 to 8.3)
SecondaryParticipants With No Residual Tumor After Metastatic Surgery

Participants with no residual tumor after on-study surgery for metastases

Time frame:
time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
Reported as:
Number · Participants
Participants With No Residual Tumor After Metastatic Surgery
ParticipantsCetuximab Plus FOLFIRIFOLFIRI Alone
Participants With No Residual Tumor After Metastatic Surgery2910
Statistical analysis
  • Cetuximab Plus FOLFIRI vs FOLFIRI Alone · Cochran-Mantel-Haenszel · p = 0.002 · Odds ratio (or): 3.02 · 95% CI 1.45 to 6.27
SecondaryQuality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

Time frame:
at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Least squares mean · scores on a scale
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
scores on a scaleCetuximab Plus FOLFIRIFOLFIRI Alone
At baseline58.88 ± 1.18560.33 ± 1.155
At week 859.02 ± 1.18761.83 ± 1.176
At week 1660.77 ± 1.27663.29 ± 1.249
At week 2461.83 ± 1.36864.06 ± 1.364
At week 3259.68 ± 1.59065.07 ± 1.612
At week 4063.43 ± 1.83564.02 ± 1.991
SecondaryQuality of Life Assessment (EORTC QLQ-C30) Social Functioning

Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.

Time frame:
at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Reported as:
Least squares mean · scores on a scale
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
scores on a scaleCetuximab Plus FOLFIRIFOLFIRI Alone
At baseline75.21 ± 1.42677.28 ± 1.395
At week 874.14 ± 1.43076.71 ± 1.415
At week 1673.72 ± 1.53376.67 ± 1.498
At week 2476.31 ± 1.64477.98 ± 1.633
At week 3274.04 ± 1.90375.64 ± 1.933
At week 4076.58 ± 2.19878.07 ± 2.388
SecondarySafety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for further details

Time frame:
time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
Reported as:
Number · participants
Safety - Number of Patients Experiencing Any Adverse Event
participantsCetuximab Plus FOLFIRIFOLFIRI Alone
Safety - Number of Patients Experiencing Any Adverse Event599597

Adverse events

Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab Plus FOLFIRI—263/600 (43.8%)593/600 (98.8%)
FOLFIRI Alone—204/602 (33.9%)591/602 (98.2%)
Most frequent serious events
Showing 10 of 275
Most frequent serious events
EventCetuximab Plus FOLFIRIFOLFIRI Alone
NEUTROPENIABlood and lymphatic system disorders37/60035/602
DIARRHOEAGastrointestinal disorders36/60021/602
PYREXIAGeneral disorders26/60021/602
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders20/60010/602
FEBRILE NEUTROPENIABlood and lymphatic system disorders16/60013/602
DEHYDRATIONMetabolism and nutrition disorders16/60012/602
VOMITINGGastrointestinal disorders15/60016/602
ABDOMINAL PAINGastrointestinal disorders14/60013/602
HYPOMAGNESAEMIAMetabolism and nutrition disorders13/6001/602
ILEUSGastrointestinal disorders10/6007/602
Most frequent other events
Showing 10 of 50
Most frequent other events
EventCetuximab Plus FOLFIRIFOLFIRI Alone
DIARRHOEAGastrointestinal disorders377/600353/602
NAUSEAGastrointestinal disorders322/600359/602
NEUTROPENIABlood and lymphatic system disorders272/600249/602
RASHSkin and subcutaneous tissue disorders270/60023/602
VOMITINGGastrointestinal disorders194/600231/602
ALOPECIASkin and subcutaneous tissue disorders224/600229/602
FATIGUEGeneral disorders192/600186/602
STOMATITISGastrointestinal disorders169/600110/602
ANOREXIAMetabolism and nutrition disorders169/600149/602
ABDOMINAL PAINGastrointestinal disorders142/600154/602

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cetuximab Plus FOLFIRIFOLFIRI AloneTotal
Mean60.0 ± 10.5259.8 ± 11.0659.9 ± 10.79
Age, Customized
Age, Customized(participants)Cetuximab Plus FOLFIRIFOLFIRI AloneTotal
Missing101
Between 18 and 65 years374377751
>=65 years224222446
Gender
Gender(Participants)Cetuximab Plus FOLFIRIFOLFIRI AloneTotal
Female230243473
Male369356725
Region of Enrollment
Region of Enrollment(participants)Cetuximab Plus FOLFIRIFOLFIRI AloneTotal
Western Europe262267529
Eastern Europe203201404
Rest of the World134131265
08

Study locations

154 sites
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Bedford Park, Australia
  • Research Site
    Darlinghurst, Australia
  • Research Site
    Heidelberg, Australia
  • Research Site
    Nedlands, Australia
  • Research Site
    West Perth, Australia
  • Research Site
    Woodville, Australia
  • Research Site
    Innsbruck, Austria
  • Research Site
    Klagenfurt, Austria
  • Research Site
    Kufstein, Austria
  • Research Site
    Salzburg, Austria
  • Research Site
    St. Pölten, Austria
  • Research Site
    St. Veit an der Glan, Austria
  • Research Site
    Wels, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Bonheiden, Belgium
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Liège, Belgium
  • Research Site
    Goiania, Brazil
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Santo André, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Plovidiv, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Santiago-Las Condes, Chile
  • Research Site
    Santiago-Providencia, Chile
  • Research Site
    Chomutov, Czech Republic
  • Research Site
    Prague, Czech Republic
  • Research Site
    Turku, Finland
  • Research Site
    Bordeaux, France
  • Research Site
    Boulogne-Billancourt, France
  • Research Site
    Colmar, France
  • Research Site
    Grenoble, France
  • Research Site
    La Roche sur Yon, France
  • Research Site
    Lorient, France
  • Research Site
    Marseille, France
  • Research Sites
    Nantes, France
  • Research Site
    Perigueux, France
  • Research Site
    Rennes Cedex, France
  • Research Site
    Saint Gregoire, France
  • Research Site
    Strasbourg, France
  • Research Site
    Toulon, France
  • Research Site
    Villejuif Cedex, France
  • Research Site
    Dortmund, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Düsseldorf, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Frankfurt am Main, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Göttingen, Germany
  • Research Site
    Halle, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Homburg/Saar, Germany
  • Research Site
    Jena, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Mannheim, Germany
  • Research Site
    München, Germany
  • Research Site
    Oldenburg, Germany
  • Research Site
    Ulm, Germany
  • Research Site
    Alexandroupolis, Greece
  • Research Site
    Athens, Greece
  • Research Site
    Heraklion, Greece
  • Research Site
    Pokfulam, Hong Kong
  • Research Site
    Shatin, Hong Kong
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Györ, Hungary
  • Research Site
    Kecskemét, Hungary
  • Research Site
    Pécs, Hungary
  • Research Site
    Ancona, Italy
  • Research Site
    Aviano, Italy
  • Research Site
    Bari, Italy
  • Research Site
    Benevento, Italy
  • Research Site
    Firenze, Italy
  • Research Site
    Mantova, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Modena, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Reggio Emilia, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Rozzano, Italy
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Mexico, Mexico
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Apeldoom, Netherlands
  • Research Site
    Blaricum, Netherlands
  • Research Site
    Den Haag, Netherlands
  • Research Site
    Roosendaal, Netherlands
  • Research Site
    Zwolle, Netherlands
  • Research Site
    Bialystok, Poland
  • Research Site
    Gliwice, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Opole, Poland

Showing the first 100 of 154 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019. PubMed 19339720 ↗
  • Van Cutsem E, Lang I, Folprecht G, Nowacki M, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Celik I, Kohne C Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, USA January 2010 Abstract No: 281
  • Lang I, Kohne CH, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Zubel A, Van Cutsem E Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial. European Journal of Cancer Supplements. 2009 7(2):345
  • Dercle L, Lu L, Lichtenstein P, Yang H, Wang D, Zhu J, Wu F, Piessevaux H, Schwartz LH, Zhao B. Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. JCO Clin Cancer Inform. 2017 Nov;1:1-8. doi: 10.1200/CCI.17.00108. PubMed 30657405 ↗
  • Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797. Erratum In: JAMA Oncol. 2017 Dec 1;3(12):1742. doi: 10.1001/jamaoncol.2017.4136. PubMed 27722750 ↗
  • Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19. PubMed 23265711 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Dec 2006 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
May 2004
Primary completionActual
Dec 2006
CompletionActual
Mar 2011
Results first posted
Feb 23, 2011
Last update
Jan 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00154102
First posted
Sep 12, 2005
Start date
May 2004
Primary completion
Dec 2006
Completion
Mar 2011
Results posted
Feb 23, 2011
Last update
Jan 30, 2017

Study contacts

Eric van Cutsem, Professor
principal investigator · University Hospital Gasthuisberg, Department Internal Medicine, Leuven, Belgium

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion